Fig. 1 · Structure

Documents & Downloads

Chloramphenicol

Cat. No. A10200 CAS 56-75-7
Chloramphenicol is a bacteriostatic antimicrobial.

In Stock

Publications for Chloramphenicol

2 publications citing this product

  1. Yixin Yu, .et al. , Exp Eye Res, 2025, Feb:251:110245 PMID: 39848559
  2. Shuang Luo, .et al. , Nat Commun, 2024, 15: 3780 PMID: 38710714

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Chloramphenicol inhibits ribosomal translation in a nascent-peptide-dependent manner. In a cell-free model, elongation proceeded to a susceptible sequence context before arrest; the reported 98 ± 2% arrest at 1 μM is an assay-specific fraction, not an IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
JNK  
MMP13  

In Vitro Studies

At 200 µg/mL for 7 days, chloramphenicol reduced mitochondrial MT-CO2/MT-ND3 proteins and cytochrome c oxidase maximal activity in SH-SY5Y cells and iPSC-derived forebrain neurons. Basal oxygen consumption decreased in SH-SY5Y cells but increased in the neurons; viability was comparable to untreated controls in both models. [2]

In H1299 lung cancer cells, chloramphenicol reduced cellular ATP while increasing transwell invasion. This model-specific result cautions against assuming that mitochondrial inhibition uniformly reduces cancer-cell invasive behavior. [3]

Context-dependent arrest in a cell-free translation system

Biochemical assay · Fluorescently labelled Escherichia coli ribosomes translating model mRNA; no-drug control. [1]

Chloramphenicol arrested progression at the susceptible nascent-peptide context rather than preventing all elongation steps. Toeprinting compared susceptible and non-arresting contexts.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ribosomes halted at the F5 arrest site on the MFKAFK templatearrest fraction 98 ± 2% at 1 μM CHL[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM for the Figure 2 smFRET experiment; 50 μM in the separate Figure 1 toeprinting validation.
Exposure duration
8-minute smFRET recordings; toeprinting translation for 15 minutes.
Method
Cell-free translation monitored by smFRET; toeprinting used for context controls.
Co-treatment
Chloramphenicol alone; linezolid and thiostrepton were separate comparator conditions.
Reported limits
CHL stock solvent not specified in the selected methods; single-molecule n is not biological replication.
Methods and source locations

Compound reported in the paper: Chloramphenicol; Compound label in the paper: CHL

Evidence concerns the named research compound in the stated model; no Adooq sourcing or lot-specific performance is established.

Figures 1a–b and 2b–d; Results first two subsections; Online Methods: toeprinting, smFRET, statistics

Ribosomes halted at the F5 arrest site on the MFKAFK template: smFRET progression; n = 100 molecules in the CHL condition, from one experiment. Error estimated with a binomial model; n = 87 for no drug. This is not an IC50. — Results: Monitoring CHL/LZD-induced translation arrest in real time; Figure 2b–d; Online Methods: smFRET experiments and Statistics and Reproducibility

Mitochondrial effects in SH-SY5Y cells

Cell-based study · Undifferentiated human SH-SY5Y ρ+ cells versus untreated cells. [2]

Treatment reduced MT-CO2 and MT-ND3 protein and basal oxygen consumption. Trypan-blue viability was comparable to control; citrate synthase maximal activity did not significantly change.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MT-CO2 and MT-ND3 protein abundancedirection Decreased relative to untreated cells[2]
Basal OCR and COX maximal activitydirection and reported approximate change Basal OCR decreased; COX Vmax reduced by ≈85%[2]

Literature-Reported Treatment Conditions

Treatment concentration
200 µg/mL
Exposure duration
1 week (7 days)
Method
Exposure in culture; concentration maintained with medium changes.
Co-treatment
No additional experimental drug during the chronic chloramphenicol exposure; flux testing subsequently used mitochondrial stress-test reagents.
Reported limits
Chloramphenicol stock vehicle and donor-level replication are not specified in the selected treatment/statistics sections; plotted replicate counts are not inferred as independent donors.
Methods and source locations

Compound reported in the paper: Chloramphenicol; Compound label in the paper: chloramphenicol

Evidence concerns the named research compound in the stated model; no Adooq sourcing or lot-specific performance is established.

Figure 1A–B,F–I; Results 3.1; Methods 2.3–2.5,2.8,2.11–2.13

MT-CO2 and MT-ND3 protein abundance: Immunoblot densitometry normalized to β-tubulin. — Figure 1B; Results 3.1; Methods 2.5

Basal OCR and COX maximal activity: Seahorse flux normalized to cell count; spectrophotometric COX activity. Approximate percentage is from Results prose, not digitized. — Figure 1F,H; Results 3.1; Methods 2.11–2.13

Mitochondrial effects in iPSC-derived forebrain neurons

Cell-based study · Mature human forebrain neurons derived from an APOE ε3/ε3 fibroblast-derived iPSC line (JIPSC1268), versus untreated neurons. [2]

MT-CO2 and MT-ND3 protein and COX maximal activity decreased, but basal oxygen consumption increased. Basal extracellular acidification and viability were comparable to control; citrate synthase activity increased.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MT-CO2 and MT-ND3 protein abundancedirection Decreased relative to untreated neurons[2]
Basal OCR and COX maximal activitydirection and reported approximate change Basal OCR increased; COX Vmax declined by 40%[2]

Literature-Reported Treatment Conditions

Treatment concentration
200 µg/mL
Exposure duration
1 week (7 days)
Method
Exposure in culture; concentration maintained with medium changes.
Co-treatment
No additional experimental drug during the chronic chloramphenicol exposure; flux testing subsequently used mitochondrial stress-test reagents.
Reported limits
Chloramphenicol stock vehicle and donor-level replication are not specified in the selected treatment/statistics sections; plotted replicate counts are not inferred as independent donors.
Methods and source locations

Compound reported in the paper: Chloramphenicol; Compound label in the paper: chloramphenicol

Evidence concerns the named research compound in the stated model; no Adooq sourcing or lot-specific performance is established.

Figure 5A–B,H–K; Results 3.4; Methods 2.1–2.2,2.4–2.5,2.8,2.11–2.13

MT-CO2 and MT-ND3 protein abundance: Immunoblot densitometry normalized to β-tubulin. — Figure 5B; Results 3.4; Methods 2.5

Basal OCR and COX maximal activity: Seahorse flux normalized to cell count; spectrophotometric COX assay. The 40% statement is from Results prose. — Figure 5H,J; Results 3.4; Methods 2.11–2.13

Metabolic restriction and increased H1299 cell invasion

Cell-based study · Human H1299 non-small-cell lung cancer cells; zero-chloramphenicol controls; rotenone used separately as an ATP-assay positive control. [3]

Chloramphenicol decreased Cox I protein and cellular ATP, while increasing Matrigel transwell invasion. These results limit any general assertion that mitochondrial inhibition necessarily suppresses tumor-cell invasion.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular ATP contentdirection Decreased across 10, 20 and 100 μg/mL CHL conditions relative to control[3]
Invaded H1299 cells per chamberdirection Increased at 20 and 100 μg/mL relative to zero CHL[3]

Literature-Reported Treatment Conditions

Treatment concentration
ATP: 10, 20 and 100 μg/mL; invasion and Cox I: 20 and 100 μg/mL, with zero-CHL controls.
Method
Cell exposure followed by ATP assay, Cox I immunoblotting and transwell invasion assessment.
Vehicle
Ethanol; solvent content < 5 μL/mL in all experiments.
Co-treatment
CHL alone in the adopted conditions; rotenone was a separate ATP-assay comparator.
Reported limits
Figure 1 and its caption do not specify endpoint-specific treatment duration. Common invasion methods give 12–48 h, without assigning an exact interval to Figure 1C. Vehicle matching for zero-CHL wells is not explicitly stated.
Methods and source locations

Compound reported in the paper: Chloramphenicol; Compound label in the paper: chloramphenicol

Evidence concerns the named research compound in the stated model; no Adooq sourcing or lot-specific performance is established.

Figure 1A–C; first Results subsection; Materials and Methods: chemicals/cell culture, ATP, Western blot, invasion and statistics

Cellular ATP content: ATP bioluminescence; mean ± SD from at least three independent experiments under the common statistics statement. Exact bar heights not transcribed. — Figure 1B; first Results subsection; Materials and Methods: Cellular ATP content measurement and Statistical analysis

Invaded H1299 cells per chamber: Matrigel-coated transwell assay; mean ± SD, at least three independent experiments under common statistics statement. — Figure 1C; first Results subsection; Materials and Methods: In vitro invasion assay and Statistical analysis

Specifications

Manufacturer Adooq Bioscience
CAS Number 56-75-7
Formula C11H12Cl2N2O5
Molecular Weight 323.13
Synonyms chlornitromycin
SMILES
C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (170.2 mM)
Water Insoluble
Ethanol 55 mg/mL (170.2 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Choi J, Marks J, Zhang J, et al. Dynamics of the context-specific translation arrest by chloramphenicol and linezolid Nature chemical biology (2020). PMID: 31844301 DOI: 10.1038/s41589-019-0423-2 Source material
  2. [2] Gabrielli AP, Novikova L, Ranjan A, et al. Inhibiting mtDNA transcript translation alters Alzheimer's disease-associated biology Alzheimer's & dementia : the journal of the Alzheimer's Association (2024). PMID: 39441557 DOI: 10.1002/alz.14275 Source material
  3. [3] Li CH, Cheng YW, Liao PL, et al. Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion Toxicological sciences : an official journal of the Society of Toxicology (2010). PMID: 20338993 DOI: 10.1093/toxsci/kfq085 Source material

Publications

2 publications citing this product

  1. Yixin Yu, .et al. , Exp Eye Res, 2025, Feb:251:110245 PMID: 39848559
  2. Shuang Luo, .et al. , Nat Commun, 2024, 15: 3780 PMID: 38710714

Added to your cart

View Cart Checkout
Loading...